Summit Therapeutics (SMMT) Current Assets (2018 - 2026)

Summit Therapeutics has reported Current Assets for 9 years, with the latest figure at $616.6 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 66.31% year-over-year to $616.6 million; the trailing twelve-month figure through Mar 2026 stood at $616.6 million (up 66.31% YoY), and the FY2025 full-year result was $720.3 million, up 69.98% from the prior year.
• Current Assets for Q1 2026 stood at $616.6 million, down from $720.3 million in the prior quarter.
• The five-year high for Current Assets was $720.3 million in Q4 2025, with the low at $79.4 million in Q2 2022.
• Historically, Current Assets has averaged $324.3 million across 5 years, with a median of $248.0 million in 2023.
• Annual changes were most pronounced in 2022 — Current Assets surged 574.85% — and 2023, when it plunged 71.11%.
• Summit Therapeutics' Current Assets stood at $656.7 million in 2022, then sank by 71.11% to $189.7 million in 2023, then surged by 123.36% to $423.8 million in 2024, then surged by 69.98% to $720.3 million in 2025, then slipped by 14.4% to $616.6 million in 2026.
• The last three Current Assets figures came in at $616.6 million (Q1 2026), $720.3 million (Q4 2025), and $246.5 million (Q3 2025), per Business Quant data.